Information Provided By:
Fly News Breaks for December 5, 2016
AGN
Dec 5, 2016 | 06:32 EDT
JPMorgan analyst Chris Schott sees a "compelling opportunity" in shares of Allergan heading into 2017. The company is well positioned with expectations reset and a core business that is "intact and delivering healthy organic growth," Schott tells investors in a research note. He views Allergan's pipeline as underappreciated and keeps an Overweight rating on the shares with a $300 price target. Allergan closed Friday down 67c to $189.69.
News For AGN From the Last 2 Days
There are no results for your query AGN